Purchase this article with an account.
William K Stell; How does atropine inhibit myopia development? Evidence from animal studies.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3294.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Atropine is well known to prevent or slow the progression of myopia, in experimental animal models (form-deprivation myopia [FDM] and negative-lens-induced myopia [LIM]) as well as in naturally occurring human myopia. Given that atropine is known mainly as a competitive antagonist at muscarinic acetylcholine receptors (mAChR), it is widely assumed that this property is responsible for its anti-myopia effect. Myopia in a wide range of animal species (birds and mammals, including Homo sapiens) is inhibited by atropine, but not in every individual case; and surprisingly high doses are required for maximal effectiveness. I will review evidence from my lab suggesting that mAChRs may not be the target by which atropine and some other anti-muscarinic drugs inhibit myopia-development.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only